Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data

The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB). However, resistance to ETV has been reported, especially with prior exposure to other NAs, and long‐term TDF treatment has been associated with decline in renal function and loss of bone mineral density in some patients. Consequently, TAF may be preferable to ETV, TDF or other NAs in specific circumstances such as in patients with risk of bone or renal complications, elderly patients or those with previous NA experience.

[1]  Ye Gu,et al.  Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load , 2021, Hepatology International.

[2]  E. Schiff,et al.  Safety and Effectiveness of Tenofovir Alafenamide in Usual Clinical Practice Confirms Results of Clinical Trials: TARGET-HBV , 2021, Digestive Diseases and Sciences.

[3]  H. Lee,et al.  Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching from Tenofovir Disoproxil Fumarate. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  B. Conway,et al.  Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real‐World Study , 2021, Journal of viral hepatitis.

[5]  T. Ishikawa,et al.  Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice , 2021, Hepatology.

[6]  Guo-feng Chen,et al.  Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low‐level viraemia , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[7]  Juan Li,et al.  Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Brian T. Lee,et al.  Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients , 2020, JGH open : an open access journal of gastroenterology and hepatology.

[9]  T. Ide,et al.  Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B , 2020, Biomedical reports.

[10]  A. Morishita,et al.  Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B , 2020, JGH open : an open access journal of gastroenterology and hepatology.

[11]  J. Kao,et al.  IDDF2020-ABS-0058 48-week safety and efficacy of switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF) in chronic HBV asian patients with TDF risk factors (RF) , 2020 .

[12]  Hangil Lee,et al.  High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: A nationwide cohort study , 2020, Journal of viral hepatitis.

[13]  Chun-Ying Wu,et al.  Increasing Age and Nonliver Comorbidities in Patients with Chronic Hepatitis B in Taiwan: A Nationwide Population-Based Analysis , 2020, Digestive Diseases.

[14]  H. Mo,et al.  Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance , 2020, Journal of viral hepatitis.

[15]  M. Babatin,et al.  Clinical Characteristics of Hepatitis B Virus Patients After Switching to Tenofovir Alafenamide Fumarate: A Retrospective Observational Study , 2020, Cureus.

[16]  Ruochan Chen,et al.  Efficacy and safety of tenofovir alafenamide fumarate for preventing mother‐to‐child transmission of hepatitis B virus: a national cohort study , 2020, Alimentary pharmacology & therapeutics.

[17]  Chien-Hung Chen,et al.  Efficacy and safety of switching to tenofovir alafenamide for chronic hepatitis B patients with advanced fibrosis and partial virologic response to oral nucleos(t)ide analogues (ESTAB-AFPVR) - an interim report , 2020, Journal of Hepatology.

[18]  W. Kim,et al.  Longer-term experience with tenofovir alafenamide (TAF) in HBV-infected patients; changes in EGFR, FIB4, ALT, and DNA suppression , 2020, Journal of Hepatology.

[19]  W. Kim,et al.  Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice , 2020, Journal of Hepatology.

[20]  Chien-Hung Chen,et al.  Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study , 2020, Journal of Hepatology.

[21]  H. Janssen,et al.  Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study , 2020, Journal of Hepatology.

[22]  M. Buti,et al.  Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials , 2020, Journal of Hepatology.

[23]  M. Buti,et al.  A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results , 2020, Journal of Hepatology.

[24]  M. Buti,et al.  Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. , 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[25]  D. Jun,et al.  Increasing comorbidities in a South Korea insured population‐based cohort of patients with chronic hepatitis B , 2020, Alimentary pharmacology & therapeutics.

[26]  A. Tanaka.  JSH Guidelines for the Management of Hepatitis B Virus Infection: 2019 Update. , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[27]  A. Tanaka.  Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[28]  H. Nomura,et al.  Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[29]  Akihiro Tanaka,et al.  Early changes in tubular dysfunction markers and phosphorus metabolism regulators as a result of switching from entecavir to tenofovir alafenamide fumarate nucleoside analog therapy for chronic hepatitis B patients , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

[30]  W. Kim,et al.  Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  John F. Flaherty,et al.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. , 2020, The lancet. Gastroenterology & hepatology.

[32]  M. Buti,et al.  Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. , 2020, Journal of hepatology.

[33]  [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. , 2019, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[34]  M. Nakao,et al.  Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate , 2019, Journal of medical virology.

[35]  M. Kurosaki,et al.  Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate , 2019, Journal of gastroenterology and hepatology.

[36]  M. Kudo,et al.  Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B , 2019, Journal of medical virology.

[37]  V. Wong,et al.  An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory‐Wide Study From 2000 to 2017 , 2019, Hepatology.

[38]  D. J. Kim,et al.  Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[39]  Ah Ram Lee,et al.  Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. , 2019, Journal of hepatology.

[40]  KASL clinical practice guidelines for management of chronic hepatitis B , 2019, Clinical and molecular hepatology.

[41]  F. Sanai,et al.  Greater prevalence of comorbidities with increasing age: Cross-sectional analysis of chronic hepatitis B patients in Saudi Arabia , 2019, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[42]  G. Dusheiko,et al.  Advancing Age and Comorbidity in a US Insured Population‐Based Cohort of Patients With Chronic Hepatitis B , 2019, Hepatology.

[43]  A. Ahn,et al.  Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide , 2019, Journal of viral hepatitis.

[44]  I. Kim,et al.  Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate , 2018, Gut and liver.

[45]  V. Wong,et al.  Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. , 2018, Journal of hepatology.

[46]  N. Ford,et al.  Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta‐Analysis , 2018, Hepatology communications.

[47]  Kuan-Han H Wu,et al.  Mortality Among Patients With Chronic Hepatitis B Infection: The Chronic Hepatitis Cohort Study (CHeCS) , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  John F. Flaherty,et al.  Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection. , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[49]  M. Buti,et al.  96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. , 2018, Journal of hepatology.

[50]  B. McMahon,et al.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.

[51]  Sang Gyune Kim,et al.  Effect of tenofovir on renal function in patients with chronic hepatitis B , 2018, Medicine.

[52]  D. Sinn,et al.  Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment , 2017, Hepatology.

[53]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[54]  T. Tseng,et al.  Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[55]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[56]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[57]  G. Casazza,et al.  The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. , 2015, Journal of hepatology.

[58]  T. Therneau,et al.  Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B , 2015, Cancer.

[59]  R. Paredes,et al.  The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  A. Ray,et al.  Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy , 2015, Antimicrobial Agents and Chemotherapy.

[61]  John F. Flaherty,et al.  Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. , 2015, Journal of hepatology.

[62]  M. Mcphail,et al.  Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? , 2015, The Journal of infectious diseases.

[63]  L. Chan,et al.  Long-Term Treatment with Tenofovir in Asian-American Chronic Hepatitis B Patients Is Associated with Abnormal Renal Phosphate Handling , 2015, Digestive Diseases and Sciences.

[64]  C. Coffin,et al.  The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long‐term nucleos(t)ide analogue therapy , 2014, Alimentary pharmacology & therapeutics.

[65]  Jaw-Town Lin,et al.  Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. , 2014, Gastroenterology.

[66]  Yoshiyuki Suzuki,et al.  Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.

[67]  William A. Lee,et al.  Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. , 2013, Molecular pharmaceutics.

[68]  Huy A. Nguyen,et al.  Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders , 2012, Digestive Diseases and Sciences.

[69]  J. Hoofnagle,et al.  Renal tubular dysfunction during long‐term adefovir or tenofovir therapy in chronic hepatitis B , 2012, Alimentary pharmacology & therapeutics.

[70]  H. Yim,et al.  KASL Clinical Practice Guidelines: Management of chronic hepatitis B , 2012, Clinical and molecular hepatology.

[71]  Ding-Shinn Chen,et al.  High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. , 2012, Gastroenterology.

[72]  C. Bunchorntavakul,et al.  Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir , 2012, Journal of viral hepatitis.

[73]  K. Flegal.  Trends in body weight and overweight in the U.S. population. , 2009, Nutrition reviews.

[74]  William A. Lee,et al.  Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue , 2005, Antimicrobial Agents and Chemotherapy.

[75]  D R Jacobs,et al.  Weight gain continues in the 1990s: 10-year trends in weight and overweight from the CARDIA study. Coronary Artery Risk Development in Young Adults. , 2000, American journal of epidemiology.

[76]  Guías de Práctica Clínica.  European Association for the Study of the Liver , 1971 .

[77]  John F. Flaherty,et al.  Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. , 2017, Journal of hepatology.

[78]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[79]  L. Pallardo,et al.  Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Lipoprotein Ratios: Physiological Significance and Clinical Usefulness in Cardiovascular Prevention , 2022 .